Loading...
Back to narrative

ATMU: Multi-Year Outgrowth Execution Will Drive Confidence Amid Challenging Demand

Update shared on 26 Nov 2025

Fair value Increased 12%
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
9.9%
7D
3.8%

Analysts have raised their fair value estimate for Atmus Filtration Technologies from $49.20 to $55.00. They cite ongoing execution on growth opportunities, even as the company faces a challenging demand environment.

Analyst Commentary

Analyst sentiment around Atmus Filtration Technologies reflects a blend of optimism regarding the company’s execution on long-term strategies and caution about the near-term demand outlook. Recent target price adjustments signal evolving views on its valuation and market positioning.

Bullish Takeaways

  • Bullish analysts point to consistent execution on multi-year growth opportunities as a key differentiator supporting the company’s long-term valuation.
  • Recent upward revisions to fair value estimates are attributed to Atmus’s ongoing ability to capitalize on new business initiatives, even in the face of industry headwinds.
  • Leadership’s engagement with investors and transparency around financial strategy provide confidence in Atmus’s roadmap for sustained expansion.
  • The company’s focus on operational efficiency and portfolio outgrowth initiatives is cited as a contributor to resilient performance in a challenging environment.

Bearish Takeaways

  • Bearish analysts remain cautious due to the persistent softness in demand, which may limit near-term revenue growth potential.
  • Concerns persist that macroeconomic pressures and cyclical challenges could restrict the pace of future upgrades to fair value estimates.
  • The company’s ability to sustain its current momentum is viewed as uncertain if market conditions worsen further.

What's in the News

  • Completed repurchase of 1,995,964 shares, representing 2.43% for $80.65 million under the buyback announced on July 18, 2024 (Key Developments)
  • From July 1, 2025 to September 30, 2025, the company repurchased 666,854 shares for $30.3 million, representing 0.82% of shares (Key Developments)
  • Raised 2025 earnings guidance, with expected revenue in the range of $1,720 million to $1,745 million (Key Developments)

Valuation Changes

  • Fair Value Estimate has increased from $49.20 to $55.00, reflecting a higher assessment of Atmus's intrinsic worth.
  • Discount Rate has decreased slightly, from 8.67% to 8.66%, suggesting a marginally lower perceived risk or cost of capital.
  • Revenue Growth Estimate has risen modestly, from 4.47% to 4.65%, indicating improved expectations for future top-line expansion.
  • Net Profit Margin Estimate has declined slightly, from 13.92% to 13.59%, signaling a more conservative view on future profitability.
  • Future Price-to-Earnings (P/E) Ratio has increased noticeably, from 15.91x to 20.23x. This implies a higher valuation multiple being applied to expected earnings.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.